Effects of Mitoquinone on Doxorubicin-Induced Cytotoxicity in H9c2 Cardiac Myoblasts and 22Rv1 Prostate Cancer Cells

The study investigates the effects of mitoquinone (MitoQ) on doxorubicin (DOX)-induced cytotoxicity in H9c2 cardiac myoblasts and 22Rv1 prostate cancer cells. DOX is known for its cardiotoxicity, limiting its use as a chemotherapeutic agent. The study found that a 24-hour pre-treatment with MitoQ significantly protected H9c2 myoblasts from DOX-induced damage, outperforming the FDA-approved cardioprotective agent dexrazoxane (DEX). Additionally, MitoQ slightly enhanced DOX's cytotoxicity in prostate cancer cells. These results suggest that MitoQ could offer cardioprotection without compromising DOX's anti-cancer efficacy, warranting further investigation into its mechanisms.